Recent studies have focused on the convergence of GLP|GIP|GCGR stimulant therapies and dopamine communication. While GCGR stimulators are commonly employed for managing type 2 diabetes, their emerging impacts on motivation circuits, specifically governed by dopamine pathways, are attracting substantial attention. This paper provides a summary exami